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Question: Is sodium oxybate superior to placebo in improving 3 
electrophysiological measures of daytime sleepiness and sleep disturbance in 4 
Parkinson disease? 5 
Findings: In this double-blind, placebo-controlled crossover trial with 6 
including 12 patients with Parkinson disease, sodium oxybate, as compared 7 
to with placebo, significantly improved sleepiness and disturbed nighttime 8 
sleep both subjectively and objectively. However, it induced de novo 9 
obstructive sleep apnea in two 2 patients and parasomnia in one1 patient. 10 
Meaning: The study provides class I evidence for the efficacy of sodium 11 
oxybate for sleep-wake disturbances in patients with Parkinson 12 
patientsdisease, but stringent monitoring is necessary and larger follow-up 13 
trials with longer treatment durations are warranted for validation. 14 
Importance: Sleep-wake disorders are a common and debilitating non-15 
motor manifestation of Parkinson disease (PD), but treatment options are 16 
scarce. 17 
Objective: To determine whether nocturnal administration of «DT1: 18 
sodium oxybate (SO»), a first-line treatment in narcolepsy, is effective and 19 
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names are not abbreviated in 
JAMA Network journals; 
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4 
safe for excessive daytime sleepiness (EDS) and disturbed nighttime sleep in 1 
patients with PD. 2 
Design, Setting, and Participants: Randomized, double-blind, placebo-3 
controlled, crossover phase 2a study carried out between January 9, 2015, 4 
and February 24, 2017. In a Monocenter single-center study in the sleep 5 
laboratory at the University Hospital Zurich, Zurich, Switzerland, we 6 
screened 18 patients with PD and EDS (Epworth Sleepiness Scale [ESS] 7 
score >10) were screened in the sleep laboratory. 5 Five patients were 8 
excluded due to the polysomnographic diagnosis of sleep apnea and 1 9 
patient withdrew consent. Thus, 12 patients were randomized to a treatment 10 
sequence (sodium oxybate followed by /placebo or placebo followed by 11 
/sodium oxybate, ratio 1:1) and, after dropout of one 1 patient due to an 12 
unrelated adverse event during the washout period, 11 patients completed 13 
the study. Two patients developed obstructive sleep apnea under during 14 
sodium oxybate treatment (one 1 was the dropout) and were excluded from 15 
the per-protocol analysis (n = 10) but included in the intention-to-treat 16 
analysis (n = 12). 17 
Interventions: Nocturnal sodium oxybate and placebo taken at bedtime and 18 
2.5 to -4.0 hours later with an individually titrated dose between 3.0 and -9.0 19 
NBR170001.docx 
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5 
g/night for a duration of 6 weeks with a 2- to 4-week washout period 1 
interposed. 2 
Main Outcomes and Measures: Primary outcome measure was change of 3 
objective EDS score as electrophysiologically measured by mean sleep 4 
latency in the Multiple Sleep Latency Test. Secondary outcome measures 5 
included change of subjective EDS (Epworth Sleepiness ScaleESS), sleep 6 
quality (Parkinson Disease Sleep Scale–2) and objective parameters 7 
variables of nighttime sleep (polysomnography). 8 
Results: Among 12 patients in the intention-to-treat population («DT2: 10 9 
malesmen, 2 femaleswomen»; mean [SD] age, 62 [11.1] years; , mean 10 
disease duration [SD]disease duration, 8.4 [4.6] years), sodium oxybate 11 
substantially improved EDS as measured objectively (mean sleep latency, 12 
+2.9 minutes; 95% confidence interval [CI, 2.1 to 3.8 minutes; P = .002) and 13 
subjectively (ESS score, −4.2 points Epworth score; 95% CI, −5.3 to −3.0 14 
points; P = .001). Thereby, 8 (67%) of patients exhibited an 15 
electrophysiologically- defined positive treatment response. Moreover, 16 
sodium oxybate significantly enhanced subjective sleep quality and 17 
objectively measured slow- wave sleep duration (+72.7 minutes; 95% CI, 18 
55.7 to 89.7 minutes; P < .001). Differences were more pronounced in the 19 
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6 
per-protocol analysis. Sodium oxybate was generally well tolerated under 1 
dose adjustments (no treatment-related dropouts), but induced de novo 2 
obstructive sleep apnea in 2 patients and parasomnia in one1 patient, as 3 
detected by polysomnography, all of whom did not benefit from sodium 4 
oxybate treatment. 5 
Conclusions and Relevance: This study provides class I evidence for the 6 
efficacy of SOsodium oxybate in treating EDS and nocturnal sleep 7 
disturbance in patients with PD. Special monitoring with follow-up 8 
polysomnography is necessary to rule out treatment-related complications 9 
and larger follow-up trials with longer treatment durations are warranted for 10 
validation. 11 
Trial Registration: clinicaltrials.gov Identifier: NCT02111122. 12 
Introduction 13 
Excessive daytime sleepiness (EDS) and disturbed nighttime sleep are 14 
common and debilitating nonmotor symptoms of Parkinson disease (PD),
1,2
 15 
but treatment options are scarce.
3
 Therefore, a previous open-label trial has 16 
introduced sodium oxybate, a potent central nervous system depressor
4
 and 17 
first-line treatment in narcolepsy type 1,
5
 for sleep-wake disorders in patients 18 
with PD patients.
6
 While Although it demonstrateding improvement, the 19 
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7 
open-label study’s significance is limited given the lack of a control group 1 
and objective outcome measures for sleepiness. To close this gap, the 2 
present trial examineds the efficacy and safety of sodium oxybate for EDS 3 
and disturbed nighttime sleep in a double-blind, placebo-controlled 4 
electrophysiological study. 5 
Methods 6 
This crossover, phase 2a trial was carried out at the University 7 
Hospital Zurich between 01/09/2015, and 02/24/2017. It was approved by 8 
the local ethics committee/Swissmedic and registered with clinicaltrials.gov 9 
(NCT02111122). All participants gave written informed consent. 10 
We enrolled patients with PD patients (Hoehn-Yahr stage II/III) with 11 
EDS (Epworth Sleepiness Scale, [ESS] >10 points) and stable with 12 
dopaminergic medication. Exclusion criteria included: use of sleep-inducing 13 
substances,; sleep apnea, (SA); significant cognitive impairment («DT3: 14 
MoCA »<22 points), moderate to severe depression («DT4: HADS 15 
»questionnaire), and significant concomitant diseases. 16 
This crossover, phase 2a trial was carried out at University Hospital 17 
Zurich, Zurich, Switzerland, between January 9, 2015, and February 24, 18 
Comment [DT3]: expand 
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reference 
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8 
2017. It was approved by the «DT5: local ethics committee/Swissmedic»; 1 
the protocol is available in Supplement 1. All participants gave written 2 
informed consent. «DT6: X» 3 
Eligible patients were screened with baseline polysomnography to 4 
rule out sleep apnea (apnea-hypopnea index  (AHI)>«DT7: 15/h») and 5 
subsequently randomized to one 1 of two 2 treatment sequences (sodium 6 
oxybate followed by /placebo or placebo followed by /sodium oxybate, 1:1 7 
ratio). Both medications (provided by «DT8: UCB, Switzerland») were 8 
taken daily as drinkable solutions at bedtime and 2.5 to 4.0 hours later 9 
(standard regimen in narcolepsy) for a duration of 6 weeks with a 2- to 4-10 
week washout period before crossover (Figure 1). In weekly alternating 11 
telephone calls and clinical visits, the dosage was titrated between 3.0 and -12 
9.0 g/night according to efficacy and /tolerability (maximum change, of 1.5 13 
g/week). Outcome measures were evaluated in the sleep laboratory at 14 
baseline and after 6 weeks on of therapy and differences were calculated 15 
both for sodium oxybate and placebo. Treatment effects were analyzed by 16 
comparing these differences, using a linear mixed model, as described (see 17 
below). 18 
Comment [DT5]: is 
Swissmedic the name of the 
local ethics commitee? If not, 
provide the name of that 
committee. 
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9 
Primary efficacy end point was treatment effect on mean sleep latency 1 
(MSL), in with the Multiple Sleep Latency Test (MSLT) objectively 2 
quantifying EDS.
7
 Secondary end points included change of subjective EDS 3 
(assessed by ESS), sleep quality (PDSS-2, questions 1-3), objective sleep 4 
parameters (in 7-hour nighttime polysomnography
7,8
), OFFoff-medication 5 
motor symptoms («DT9: UPDRS-III»), and quality of life («DT10: 6 
PDQ-39»). Positive treatment response was assumed when MSL increased 7 
by more than >50% or when ESS was normalized (≤10 points on the EDS). 8 
Safety was assessed by monitoring adverse events (AEs) as well as, routine 9 
laboratory and polysomnographic parametersmeasures. 10 
Statistical Analysis 11 
Statistical analysis (using R, version 0.999375-42)
9,10
) was primarily 12 
by intention-to-treat and secondarily by per protocol. For efficacy analysis, a 13 
linear mixed model was applied with treatment as a fixed factor (subjects 14 
participants and treatment sequence as random factors). For evaluating 15 
carryover and period effects, we used time and sequence as fixed factors. 16 
«DT11: P- values »were obtained by likelihood ratio tests11 and 17 
significance was accepted at P < .05. We furthermore performed Pearson 18 
correlation to relate changes of sleep and EDS and multivariate logistic 19 
Comment [DT9]: Expand 
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10 
regression analysis to identify predictors estimators of treatment responseds 1 
(independent variables: baseline values for age, Hoehn-Yahr stage, disease 2 
duration, UPDRS-III, ESS, MSL, and levodopa equivalent dose). 3 
Calculation of sample size was based on previous open-label study results
6
 4 
and yielded 12 samples. 5 
Results 6 
We screened 18 patients in the sleep laboratory, five 5 of whom were 7 
excluded due to the polysomnographic diagnosis of sleep apnea,SA  and one 8 
1 patient withdrew consent (Figure 1). Thus, 12 patients were randomized 9 
(10 males/men and 2 femaleswomen;, mean [SD] age,  [standard deviation] 10 
62 [11.1] years;, disease duration, 8.4 [4.6] years), see (eTable 1 in the 11 
Supplement 2) and, after dropout of one 1 patient due to an unrelated 12 
adverse event (AE) during washout, 11 patients completed the study. Two 13 
patients developed «DT12: new-onsetde novo »sleep apnea on during 14 
sodium oxybate treatment (1 was the patient who dropped -out) and were 15 
excluded for the per- protocol analysis (n = 10) but included in the intention-16 
to-treat analysis (n = 12). Mean baseline measures of EDS were 3.3 (3.0) 17 
minutes in MSLT and 14.3 (2.3) points in ESS. Final doses of study 18 
Comment [DT12]: revised 
for consistency with abstract 
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11 
medication were 4.8 g (1.5 g) for sodium oxybate and «DT13: 8.7 g (0.6 1 
g) »for placebo. No carryover or period effect was detected. 2 
In the efficacy analysis as intention-to-treat, sodium oxybate 3 
improved EDS both objectively (+2.9 minutes «DT14: on MSLT»; 95% 4 
CI, 2.1 to 3.8 minutes; P = .002) (Figure 2A) and subjectively (−4.2 points 5 
on ESS; 95% CI, −5.3 to −3.0  points; P = .001) (Figure 2B), which was 6 
even more pronounced in the per-protocol analysis (+3.5 minutes on MSLT, 7 
P < .001; −5.2 points on ESS, P < .001); raw data are available in eTable 2 8 
in the Supplement 2). Responder rate was 67%, as in eight 8 patients the 9 
«DT15: MSLT score »increased clinically significantly by more than 10 
>50% on during sodium oxybate treatment (placebo: 1 patient), while in 6 11 
(50%) patients the ESS score normalized (placebo: none). None of the 12 
clinical baseline parameters variables predicted treatment response in a 13 
multivariate logistic regression analysis. 14 
Sodium oxybate enhanced subjective sleep quality (−2.0 points on 15 
PDSS-2; 95% CI, −2.8 to −1.2 points; P = .0216), (Figure 2C) and slow-16 
wave sleep duration (+72.7 minutes of stage N3 sleep; 95% CI, 55.7 to 89.7; 17 
P < .001)= .0002, (Figure 2D), mainly at the expense of superficial stage N1 18 
sleep. Accordingly, slow-wave energy, a marker of deep sleep accumulation, 19 
Comment [DT13]: what 
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Comment [DT14]:  addition 
of "Test" correct? 
Comment [DT15]: edit 
correct? if not, this sounds like 
the length to sleep increased 
NBR170001.docx 
Confidential: Embargoed. Do Not Distribute. 
 
12 
increased significantly (+9.9 mV
2 • s; 95% CI, 7.3 to 12.5 mV2 • s; P < .001) 1 
with 2 major increments in time-locked response to the intake of the first and 2 
second doses of sodium oxybate (Figure 2E). Otherwise, no significant 3 
changes were found regarding other parameters variables of nighttime sleep, 4 
fatigue, motor symptoms, or quality of life (eTable 2 in the Supplement 2). 5 
In the per-protocol analysis, improvements in objective EDS and nocturnal 6 
slow- wave sleep correlated significantly (Pearson r = 0.8; P = .006) (Figure 7 
2F). 8 
The safety profile of sodium oxybate seemed benign (Table). 9 
Although every patient (100%) experienced AEs on while receiving sodium 10 
oxybate, the latter effects were mainly of mild (not interfering with daily 11 
activities; 75% of AEs) or maximally moderate intensity (mild to -moderate 12 
interference, 25% of AEs), intensity and largely «DT16: faded resolved 13 
»after dose adjustment (58% of AEs, in 67% of patients). Thus, only 4 14 
patients (33%) remained affected at study termination and none dropped out 15 
due to an sodium oxybate–-related AE. These individuals also displayed 16 
sleep abnormalities in polysomnography on while receiving sodium oxybate 17 
treatment (2 with sleep apnea, 1 with NREM non–rapid eye movement 18 
parasomnia, 1 with increased periodic limb movements that were,  already 19 
Comment [DT16]: Edit OK? 
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13 
present during placebo treatment) and were non-responders regarding EDS 1 
or sleep troubles. No significant increase of the mean apnea-hypopnea index 2 
or sign of abuse or /dependency was noted. 3 
Discussion 4 
The present study provides class I evidence for the efficacy of sodium 5 
oxybate in treating sleep-wake disturbances in PD. This finding is based on 6 
the extensive, electrophysiologically proven treatment effect whichthat, to 7 
our knowledge, is unmatched by any other intervention reported so far.
3,12,13
 8 
Under the premise of stringent monitoring (including regular clinical and 9 
polysomnographic follow-up), the safety profile seems benign as no sodium 10 
oxybate–related AE led to study discontinuation; however, , but further 11 
studies with longer treatment durations and larger sample sizes are 12 
warranted. 13 
Intriguingly, «DT17: tThere »was a reciprocal relationship 14 
association between nighttime sleep and EDS, as sodium oxybate–related 15 
improvements of sleep and EDS correlated significantly, whereas sodium 16 
oxybate–induced sleep disturbances predicted insufficient treatment 17 
response and side effectsAEs. 18 
Comment [DT17]: Paragrap
hs must contain more than 1 
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14 
Limitations 1 
«TG18: The main limitation of the present study is the limited 2 
number of participants. »«TG19: However, in accordance with the 3 
initial calculation of sample size, the strong therapy effect did not warrant 4 
higher numbers. »Moreover, our efficacy and safety results correspond with 5 
evidence from large narcolepsy trials
14,15
 and the study by Ondo et al,
6
 with 6 
few exceptions. For instance, we found no effect on fatigue, which may be 7 
related to differences in study population (eg, lower baseline fatigue level), 8 
placebo-controlled study design, or lower final sodium oxybate dosage. 9 
Conclusions 10 
«DT20: In »summary, sSodium oxybate may be a powerful novel 11 
treatment option for sleep-wake disturbances in PD, but stringent monitoring 12 
is necessary (as already established in many countries for sodium oxybate in 13 
narcolepsy through regulatory restrictions
6,14
) and larger follow-up trials 14 
with longer treatment durations are warranted for validation. 15 
Article Information 16 
Accepted for Publication: August 6, 2017. 17 
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 Abbreviations: SO, sodium oxybate; AE indicates adverse event; 1 
SAS, sleep apnea syndrome.; AE, adverse event 2 
Figure 2. Effect of Placebo vs Sodium Oxybate on Excessive Daytime 3 
Sleepiness and Nighttime Sleep 4 
A, Objective excessive daytime sleepiness (measured by changes of 5 
mean sleep latency in MSLT (the Multiple Sleep Latency Test 6 
(MSLT); (baseline vs treatment). B, Subjective excessive daytime 7 
sleepiness (measured by changes in the Epworth Sleepiness Scale 8 
of (ESS) (Epworth sleepiness scale). C, Objective nighttime sleep (as 9 
measured by changes of in durations of different sleep stages in 10 
noted on polysomnography (PSG) (polysomnography). D, Subjective 11 
nighttime sleep (as measured by the Parkinson Disease Sleep 12 
Scale–2 (PDSS-2), questions 1-3, regarding general sleep quality 13 
and / disturbances with initiation  and/  maintenance of aining sleep). 14 
E, Cumulative slow-wave energy, plotted longitudinally over the 15 
course of the polysomnography PSG night. The (x-axis shows: 16 
percentiles of individual sleep time; arrows indicate mean time points 17 
of sodium oxybate and/ placebo intake, (ie, at lights off and 2.5-4.0 18 
hours later). Panel F, shows the cCorrelation between change of 19 
slow- wave sleep duration and change of objective excessive daytime 20 
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sleepiness (measured by mean sleep latency) under during sodium 1 
oxybate treatment. Red dots indicate those 2 patients that who 2 
developed a sleep apnea syndrome under during sodium oxybate 3 
treatment and that were excluded in from the per-protocol analysis. 4 
Data are presented as means;, error bars indicate SD standard 5 
deviation (exception:  standard error of the meanSE for panel C for 6 
better overview). REM indicates rapid eye movement. 7 
Table. Safety Analysis
a
 8 
Adverse Events No. (%) 
Sodium Oxybate 
(n = 12) 
Placebo 
(n = 12) 
Patients 
Affected 
Adverse 
Events 
Patients Adverse 
Events 
Any adverse event 12 (100) 28 (100) 5 (42) 10 (100) 
  Adverse events unrelated to 
study medication 
3 (25) 4 (14) 3 (25) 5 (50) 
  Adverse events potentially 
related to study medication 
12 (100) 24 (86) 3 (25) 5 (50) 
    Of mMild intensity 8 (67) 18 (75)  3 (100) 5 (100) 
    Of mModerate intensity 4 (33) 6 (25) 0 (0 0 (0) 
    Of sSevere intensity 0 (0) 0 (0) 0 (0 0 (0) 
    With iImprovement after 
dose adjustment or/ 
spontaneously 
12 (100) 14 (58) 3 (25) 4 (80) 
      Mild dizziness and asthenia 6 (50) 6 (43) 1 (8) 1 (25) 
      Mild nausea 2 (17) 2 (14) 0 0 
      Mild deterioration of PD 
motor symptoms 
1 (8) 1 (7) 0 0 
      Mild thoracic discomfort 1 (8) 1 (7) 1 (8) 1 (25) 
      Short episode with dyspnea 
at night 
1 (8) 1 (7) 0 0 
      Mild leg cramps 1 (8) 1 (7) 0 0 
      Nocturesis (once) 1 (8) 1 (7) 0 0 
      Mild diarrhea 1 (8) 1 (7) 0 0 
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Confidential: Embargoed. Do Not Distribute. 
 
23 
      Mild dry mouth 0 0 1 (8) 1 (25) 
      Mild headache 0 0 1 (8) 1 (25) 
    Without improvement after 
dose adjustment 
4 (33) 10 (42) 1 (8) 1 (20) 
      Obstructive sleep apnea 
syndromeb (PSG) 
2 (17) 2 (20) 0 0 
      NREM parasomniab (PSG) 1 (8) 1 (10) 0 0 
      Increased periodic limb 
movementbs (PSG) 
  1 (8) 1 (100) 
      Moderate weight loss 1 (8) 1 (10) 0 0 
      Moderate nervousness 1 (8) 1 (10) 0 0 
      Moderate dizziness 2 (17) 2 (20) 0 0 
      Moderate deterioration of 
motor symptoms 
2 (17) 2 (20) 0 0 
      Mild lack of drive 1 (8) 1 (10) 0 0 
Abbreviations: NREM, non–rapid eye movement; PD, Parkinson disease. 1 
a
Data are in number of patients with an adverse event (percentage within 2 
study population) and total number of adverse events (percentage of all 3 
adverse events in the respective category). No severe adverse events were 4 
reported and no patients dropped out due to treatment-related adverse events. 5 
Abbreviations: PD, Parkinson Disease; PSG, polysomnography; NREM, non 6 
rapid eye movement.  7 
b
Determined on polysomnography. 8 
 9 
 10 
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